It is not surprising that physicians are reluctant to question the necessity of β blockers in patients with heart failure with preserved ejection fraction (HFpEF).
1Should a stable patient tolerating all prescribed medications really be challenged to change their regimen? Does it seem rational?
- Musse M
- Lau JD
- Yum B
- Pinheiro LC
- Curtis H
- Anderson T
- Steinman MA
- Meyer M
- Dorsch M
- Hummel SL
- Goyal P
Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction.
Am J Cardiol. 2023; 193: 70-74
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Cardiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction.Am J Cardiol. 2023; 193: 70-74
- Polypharmacy in older adults hospitalized for heart failure.Circ Heart Fail. 2020; 13e006977
- Letter by Cogswell et al regarding article, “polypharmacy in older adults hospitalized for heart failure”.Circ Heart Fail. 2021; 14e008160
- Reduced reimbursement for cardiovascular services by the Centers for Medicare and Medicaid Services: perspective from interventional cardiology.JACC Cardiovasc Interv. 2009; 2: 894-896
- Introduction, cancellation, and future promise of medicare cardiac episode payment models.Circ Cardiovasc Qual Outcomes. 2018; 11e004345
Published online: March 13, 2023
Received: February 9, 2023
Publication stageIn Press Journal Pre-Proof
See page 1 for disclosure information.
© 2023 Elsevier Inc. All rights reserved.